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Abstract
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle that presents as a
hypermetabolic response to potent volatile anesthetic gases such as halothane, sevoflurane,
desflurane and the depolarizing muscle relaxant succinylcholine, and rarely, in humans, to stresses
such as vigorous exercise and heat. The incidence of MH reactions ranges from 1:5,000 to
1:50,000–100,000 anesthesias. However, the prevalence of the genetic abnormalities may be as
great as one in 3,000 individuals. MH affects humans, certain pig breeds, dogs, horses, and probably
other animals. The classic signs of MH include hyperthermia to marked degree, tachycardia,
tachypnea, increased carbon dioxide production, increased oxygen consumption, acidosis, muscle
rigidity, and rhabdomyolysis, all related to a hypermetabolic response. The syndrome is likely to be
fatal if untreated. Early recognition of the signs of MH, specifically elevation of end-expired carbon
dioxide, provides the clinical diagnostic clues. In humans the syndrome is inherited in autosomal
dominant pattern, while in pigs in autosomal recessive. The pathophysiologic changes of MH are
due to uncontrolled rise of myoplasmic calcium, which activates biochemical processes related to
muscle activation. Due to ATP depletion, the muscle membrane integrity is compromised leading
to hyperkalemia and rhabdomyolysis. In most cases, the syndrome is caused by a defect in the
ryanodine receptor. Over 90 mutations have been identified in the RYR-1  gene located on
chromosome 19q13.1, and at least 25 are causal for MH. Diagnostic testing relies on assessing the
in vitro contracture response of biopsied muscle to halothane, caffeine, and other drugs. Elucidation
of the genetic changes has led to the introduction, on a limited basis so far, of genetic testing for
susceptibility to MH. As the sensitivity of genetic testing increases, molecular genetics will be used
for identifying those at risk with greater frequency. Dantrolene sodium is a specific antagonist of
the pathophysiologic changes of MH and should be available wherever general anesthesia is
administered. Thanks to the dramatic progress in understanding the clinical manifestation and
pathophysiology of the syndrome, the mortality from MH has dropped from over 80% thirty years
ago to less than 5%.
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Malignant hyperthermia (MH) is a hypermetabolic
response to potent inhalation agents (such as halothane,
sevoflurane, desflurane), the depolarizing muscle relaxant
succinylcholine, and rarely, in humans, to stresses such as
vigorous exercise and heat. The majority of patients with
Central Core Disease (CCD), an inherited myopathy char-
acterized by muscle weakness, are susceptible to MH.
Multi-Minicore Disease (MmCD) also predisposes to epi-
sodes of MH.
As almost all patients who are MH susceptible have no
phenotypic changes without anesthesia, it is impossible to
diagnose susceptibility without either the exposure to the
"trigger" anesthetics or by specific diagnostic testing. The
key diagnostic features include an unexplained elevation
of expired carbon dioxide, muscle rigidity and rhabdomy-
olysis, hyperthermia, acidosis and hyperkalemia.
Diagnostic criteria
The diagnosis of MH is based on clinical presentation or
laboratory testing (see the section on diagnostic meth-
ods).
The principal diagnostic features of MH are unexplained
elevation of end-tidal carbon dioxide (ETCO2) concentra-
tion, muscle rigidity, tachycardia, acidosis, hyperthermia,
and hyperkalemia. The variability in the order and time of
onset of signs often makes the clinical diagnosis rather dif-
ficult.
A clinical grading scale was developed by Larach and col-
leagues [1] in order to assist in clinical diagnosis. The ele-
ments of the scale are given in the Table 1. Differential
weighting is given to each of the manifestations of the syn-
drome. However, the scale lacks sensitivity since not all
tests may be performed in an individual episode.
The value of the grading scale is mainly in identifying
those subjects with the most convincing episodes of MH
for subsequent evaluation of the sensitivity and specificity
of the diagnostic tests. The clinical grading scale is useful
in evaluating clinical episodes in those cases in which the
subject is rated a 6 (almost certainly MH), but lower
scores should not be considered for actual diagnosis.
Epidemiology
The incidence of MH episodes during anesthesia is
between 1:5,000 and 1:50,000–100,000 anesthesias. Even
though a MH crisis may develop at first exposure to
anesthesia with those agents known to trigger an MH epi-
sode, on average, patients require three anesthesias before
triggering. Reactions develop more frequently in males
than females (2:1). All ethnic groups are affected, in all
parts of the world. The highest incidence is in young peo-
ple, with a mean age of all reactions of 18.3 years. It has
been found that children under 15 years age comprised
52.1% of all reactions. Although described in the new-
born, the earliest reaction confirmed by testing is six
months of age [2]. The oldest is 78 years.
Genetically, MH is an autosomal dominant condition; the
estimated prevalence of the genetic abnormalities may be
as great as one in 3,000 individuals (range 1:3,000 to
1:8,500).
Numerous factors could be involved in triggering MH –
age, type of anesthetic, environmental temperature, miti-
gating drugs administered simultaneously, and degree of
stress [3]. Mauritz et al. [4] found an incidence of 1:37,500
in patients who had been diagnostically tested, which was
similar to the incidence estimated by Robinson et al.
(1:30,000) [5], although wide variability has been
reported. A recent report suggested that the MH suscepti-
ble (MHS) trait may be present in 1:2,000–3,000 of the
French population [6]. Bachand and colleagues examined
the incidence of MH in Quebec, Canada, where many
families had been biopsied [7]. They traced the pedigrees
of the patients to the original immigrants from France and
found an incidence of MH susceptibility of 0.2% in this
province. However, that represented only five extended
families.
MH crises develop not only in humans but in other spe-
cies, particularly pigs, which have been a valuable source
for research. Reactions have also been described in horses,
dogs and other animals [8].
Clinical description
MH may occur at any time during anesthesia and in the
early postoperative period. The earliest signs are tachycar-
dia, rise in end-expired carbon dioxide concentration
despite increased minute ventilation, accompanied by
muscle rigidity, especially following succinylcholine
administration. Body temperature elevation is a dramatic
but often late sign of MH. Nevertheless, core temperature
should be monitored in all patients undergoing general
anesthesia for periods lasting more than 20 minutes, as
temperature elevation may be an important confirmatory
sign.
Other signs include acidosis, tachypnea and hyperkale-
mia. The progression of the syndrome may be rapid and
dramatic, particularly if precipitated by succinylcholine,Orphanet Journal of Rare Diseases 2007, 2:21 http://www.OJRD.com/content/2/1/21
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or more slower and not become manifest until after sev-
eral hours of anesthesia.
All inhalation anesthetics except nitrous oxide are triggers
for MH. The muscle relaxant succinylcholine is also a trig-
ger for MH. No other anesthetic drugs appear to be trig-
gers, including propofol and ketamine. Neither are
catecholamines, nondepolarizing muscle relaxants, cate-
chol congeners, digitalis or similar agents [9].
Although ETCO2 is a sensitive early sign of MH, in recent
years, with a decline in the use of succinylcholine, rather
than an abrupt rise in C02, a more gradual rise is often
noted. Indeed, by increasing minute ventilation it is pos-
sible to mask this rise [10].
Hyperthermia, when it occurs, is marked by increase in
core temperature at a rate of 1–2°C every five minutes.
Severe hyperthermia (core temperature greater than
44°C) may occur, and lead to a marked increase in oxygen
consumption, carbon dioxide production, widespread
vital organ dysfunction, and disseminated intravascular
coagulation (DIC) [11].
Uncontrolled hypermetabolism leads to cellular hypoxia
that is manifested by a progressive and worsening meta-
bolic acidosis. If untreated, continuing myocyte death and
rhabdomyolysis result in life-threatening hyperkalemia;
myoglobinuria may lead to acute renal failure. Additional
life-threatening complications include DIC, congestive
heart failure, bowel ischemia, and compartment syn-
drome of the limbs secondary to profound muscle swell-
ing, and renal failure from rhabdomyolysis. Indeed, when
body temperature exceeds approximately 41°C, DIC is the
usual cause of death.
Succinylcholine induced masseter muscle rigidity
Succinylcholine induced masseter muscle rigidity (MMR)
occurs in 1 in 100 children with anesthesia induced by
halothane and given succinylcholine [12]. The incidence
is probably the same following induction with sevoflu-
rane, but much less following induction with thiopental
[13]. The clinical incidence of MH as defined by arterial
blood gas changes is about 15% after MMR. However,
muscle biopsy reveals that 50% of patients experiencing
MMR are MH susceptible [14]. Patients with generalized
rigidity along with MMR are at much greater risk for MH.
Kaplan (personal communication, 1995) has hypothe-
sized that children with "jaws of steel" after succinylcho-
line as opposed to mild rigidity are at greater risk for MH.
He has hypothesized that the children with the more dra-
matic masseter rigidity are more often referred for biopsy
and hence the high incidence of positive biopsies.
Since MMR may presage MH, it is most advisable to dis-
continue the anesthetic after MMR. In an emergency, the
anesthesia may continue with "non-trigger" drugs. Fol-
lowing MMR, patients should be admitted to an intensive
care unit and monitored for signs of MH. Rhabdomyoly-
sis occurs in virtually all patients experiencing MMR and
the creatine kinase (CK) values should be checked regu-
larly. Dantrolene should be administered if the other
signs of MH occur along with MMR. Muscle biopsy for
definitive diagnosis should be carefully considered.
Central Core Disease and other myopathies
Central Core Disease (CCD) is a rare non progressive
myopathy with autosomal dominant inheritance, pre-
senting in infancy and characterized by hypotonia and
proximal muscle weakness. A few families demonstrate
autosomal recessive inheritance. Histological examina-
tion of affected muscles shows a predominance of type I
fibres containing clearly defined areas (cores) lacking oxi-
dative enzyme activity [15].
An important feature of CCD is its close association with
MH susceptibility. CCD patients are often susceptible to
MH by in vitro contracture testing (IVCT), but MH and
CCD phenotypes do not always co-segregate within fami-
lies. Patients with MH may present with cores despite
Table 1: Criteria used in the Clinical Grading Scale for Malignant Hyperthermia
Clinical Finding Manifestation
Respiratory acidosis End-tidal CO2>55 mmHg; PaCO2>60 mm Hg
Cardiac involvement Unexplained sinus tachycardia, ventricular tachycardia or ventricular fibrillation
Metabolic acidosis Base deficit >8 m/Eql
pH<7.25
Muscle rigidity Generalized rigidity; severe masseter muscle rigidity
Muscle breakdown Serum creatine kinase concentration >20,000/L units; cola colored urine; excess myoglobin in urine or serum; plasma [K+] 
>6 mEq/L
Temperature increase Rapidly increasing temperature; T >38.8°C
Other Rapid reversal of MH signs with dantrolene. Elevated resting serum creatine kinase concentration.
Family history Consistent with autosomal dominant inheritanceOrphanet Journal of Rare Diseases 2007, 2:21 http://www.OJRD.com/content/2/1/21
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being clinically asymptomatic and with some RYR1 muta-
tions (specifically some of those in the 3' transmembrane
domain of the gene) specific to CCD. A recent study
showed that RYR1 mutations are found in over 93% (25
out of 27) of Japanese patients with CCD [16]. While this
is of importance, it may not reflect the incidence of RYR1
mutations in other populations. A more recent study indi-
cated that the distribution and frequency of RYR1 muta-
tions differed markedly in the Japanese MH susceptible
population as compared to the North American and Euro-
pean MH susceptible population [17]. Although RYR1
mutations are the most common identified cause of CCD,
it does show genetic heterogeneity, with several rare sus-
ceptibility loci known (the ACTA1 gene, in association
with nemaline myopathy, and the MYH7 gene, in associ-
ation with hypertrophic cardiomyopathy), with further
loci yet to be identified [18].
At least 44 mutations have been reported in the RYR1
gene in association with CCD (reviewed in [18]). In gen-
eral terms, single point RYR1  mutations can cause (a)
CCD only, (b) MH only, (c) MH with variable CCD pen-
etrance. In this latter case, the likelihood of an RYR1
mutation resulting in both MH and CCD depends on a
number of factors including sensitivity of mutant protein
to agonists, size of the intracellular Ca2+ pool and the level
of abnormality in channel-gating (reviewed in [19]). All
individuals with the mutation should be MH susceptible,
while they may or may not have CCD. If a mutation spe-
cific to CCD is identified in a family, MH is not automat-
ically excluded as a second mutation may be present and
MH susceptibility needs to be assessed by IVCT [20]. If the
mutation has no functional studies performed it is of no
use clinically. A MH negative parent eliminates suscepti-
bility in the children.
Other myopathies that have been associated with MH sus-
ceptibility include some sodium channel forms of myoto-
nia (myotonia fluctuans), MmCD and hypokalemic
periodic paralysis [21] and Multiminicore myopathy [22].
Guis et al., 2004 found multiminicores in 16 out of 17
MHS patients [23]. The multiminicores correlated with
two missense RYR1 mutations on the same allele resulting
in the amino acid changes R2656W and T2787S [23].
More recently, recessive mutations in RYR1  have been
associated with MmCD, some of which result in altered
Ca2+ release from intracellular stores and others that do
not [24]. Taken together, these observations suggest that
there may be a subset of RYR1 mutations that result in
both MH and MmCD and a subset that are associated only
with MmCD, similar to the situation with MH and CCD.
Consequently, it will be important to distinguish between
RYR1 mutations that result in MmCD, and those that do
not.
King (or King Denborough) syndrome is a rare myopathy
characterized by dysmorphic facies, ptosis, down-slanting
palpebral fissures, hypertelorism, epicanthic folds, low-set
ears, malar hypoplasia, micrognathia, high-arched palate,
clinodactyly, palmar simian line, pectus excavatum, wing-
ing of the scapulae, lumbar lordosis and mild thoracic
scoliosis. The patents with King Denborough syndrome
also present congenital hypotonia, slightly delayed motor
development, diffuse joint hyperextensibility and mild
proximal weakness. Such patients are MH susceptible.
Etiology
Experimental evidence from a variety of sources, in vitro,
in vivo, isolated cells, transfected cells and mice who's
DNA has been altered to express one of the MH causative
mutations clearly indicates that the signs and symptoms
of MH are related to an uncontrolled release of intracellu-
lar calcium from skeletal muscle sarcoplasmic reticulum
(SR). In MH susceptible swine and in "knock-in" mice, a
variety of environmental conditions can trigger the accel-
erated calcium release such as environmental heat, exer-
cise and stress. In humans, however, MH results most
often from exposure to potent inhalation anesthetics +/-
succinylcholine. The enhanced intracellular calcium
results in activation of muscle contraction, oxygen con-
sumption, carbon dioxide production, ATP breakdown
and heat. The normal sequestration of released calcium is
inadequate and energy is expended in a futile manner, in
an attempt to lower intracellular calcium. Presumably, the
declining levels of ATP lead to failure of membrane integ-
rity and release of potassium and creatine kinase,
although the exact steps in the process have not been
definitively demonstrated.
In almost all cases, the MH susceptible patients have a
defective calcium channel located in the SR membrane.
This channel is termed the ryanodine receptor (RYR). The
channel is closely associated with other proteins and
structures, such as the dihydropyridine calcium channel
that mediates transfer of voltage change to the RYR-1
receptor. Other proteins associated with the ryanodine
receptor include triadin, and FK 506 binding protein.
However, mutations associated with MH susceptibility are
found mainly in the gene for the ryanodine receptor. As
many as 70% of families susceptible to MH harbor one of
about 30 causal mutations for MH, with approximately 40
other mutations that are yet to be characterized [25].
Transfecting cultured muscle cells or myotubes with one
of the known causal mutations results in enhanced intra-
cellular calcium release when the cells are exposed to
agents such as halothane, caffeine and chlorocresol.
Recently, a group has produced a mouse who's genome
has been altered to contain one of the causal mutations.
The animals and tissues derived from the mouse dis-Orphanet Journal of Rare Diseases 2007, 2:21 http://www.OJRD.com/content/2/1/21
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played typical MH changes and raised environmental heat
led to typical MH changes [26].
In addition, dantrolene sodium (known to reverse signs
of MH) has been found to bind to a specific ryanodine
protein site [27].
Although mutations in the ryanodine receptor are
undoubtedly important in the pathophysiology of MH, it
is also clear that not all families demonstrate linkage to
this gene. At least six other genetic loci have been impli-
cated in MH, including one that elaborates the sodium
channel [21,28] although only one other gene,
CACNL1A3, encoding the main subunit of the dihydropy-
rodine receptor (DHPR), have been shown to be altered
by an MH-linked mutation [29].
The clinical expression of MH is also poorly understood.
Genotype-phenotype correlations are weak for both the
clinical expression of MH and the response of isolated
muscle to caffeine or halothane. It therefore seems clear
that a variety of modulators influence the manifestations
of the syndrome. The fatty acids represent one set of mod-
ulators that has been studied in this respect [30,31]. Cer-
tain unsaturated fatty acids have been demonstrated to
increase the sensitivity of halothane-induced calcium
release in vitro. Such an increase in fatty acids may result
from breakdown of triglycerides as a result of enzymatic
abnormalities.
In addition, in cultured muscle cells from MH susceptible
patients there is a shift of subtypes of sodium channels
leading to a longer membrane depolarization and an
increased calcium release from the terminal cisternae [32].
Changes in sodium channel function, either through
sodium channel mutations or through effects of fatty
acids may influence the phenotypic expression of MH,
especially muscle rigidity.
Laboratory diagnostic methods
The "gold standard" for diagnosis of MH is currently the
in vitro contracture test (IVCT), which is based on contrac-
ture of muscle fibres in the presence of halothane or caf-
feine. Two widely used forms of this test have been
developed; one by the European Malignant Hyperthermia
group (EMHG) and the other by the North American
Malignant Hyperthermia Group, Caffeine Halothane
Contracture Test-CHCT (NAMHG) [33,34]. While simi-
larities exist in performing and interpreting the results of
these tests, there are significant differences. Using the
EMHG protocol, an individual is considered susceptible
to MH (MHS) when both caffeine and halothane test
results are positive. A normal MH diagnosis (MHN) is
obtained when both tests are negative. A third diagnosis,
MH equivocal (MHE), is obtained when only one of the
halothane or caffeine test is positive. Using the NAMHG
protocol, an individual is diagnosed as MHS when either
of the halothane or caffeine test is positive, and MNH
when both tests are negative. The EMHG protocol may
reduce the possibility of false positive and negative results
when compared to the NAMHG protocol but overall sim-
ilar results are obtained [35]. Sensitivity of 99% and a spe-
cificity of 94% are obtained with the EMHG protocol [36],
while figures of 97% sensitivity and 78% specificity are
reported for the NAMHG. The specificity of either proto-
col may be affected by neuromuscular disorders unrelated
to MH which have an associated increase in myoplasmic
calcium concentration. However, studies based on results
from monozygote twins indicate that the IVCT has accept-
able reproducibility [37]. A third variation of the IVCT,
the caffeine skinned fibre test, does not appear to be used
diagnostically outside of Japan, and has lower specificity
and sensitivity than either the EMGH or NAMHG proto-
cols.
IVCT is expensive, confined to specialized testing centers,
it requires a surgical procedure and can yield equivocal as
well as false positive and negative results. Modifications of
the EMHG protocol include the use of ryanodine [38]
(which binds selectively to the calcium release channel) or
4-chloro-m-cresol [39] but to date these agents have not
been included in the standard protocol. Future supplies of
halothane may be limited. A possible alternative testing
agent is the fluorinated ether, sevoflurane. Trials with this
agent are to be commenced soon. Other biochemical,
hematological and physical tests have been used in the
past but, without exception, these lack significant sensitiv-
ity and specificity to be used diagnostically.
DNA analysis, however, offers an alternative to the IVCT,
requiring only a blood specimen, which can be sent to an
accredited diagnostic laboratory. DNA testing for MH was
first suggested in 1990, when a mutation within the ryan-
odine receptor gene (RYR1) encoding the skeletal muscle
calcium release channel was identified [40]. Since then,
about 50% of MH have been linked to RYR1 with over
100 mutations associated with MH, identified within this
gene [41].
MH is, however, a heterogeneous genetic disorder with at
least five other susceptibility loci being identified.
Amongst these loci, mutations with a clear association
with MH have been identified in only one gene,
CACNA1S, encoding the alpha subunit of the dihydropy-
ridine receptor, the voltage sensor of the skeletal muscle
calcium release channel [29,42,43]. Early studies sug-
gested that mutations cluster within three regions of RYR1
(reviewed in [19]) largely because many laboratories
screen only these regions for the presence of mutations in
MH susceptible patients. Complete screening of the entireOrphanet Journal of Rare Diseases 2007, 2:21 http://www.OJRD.com/content/2/1/21
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coding regions of RYR1 has, however, revealed that muta-
tions occur in almost all regions of the gene [17,41].
While the majority of mutations lead to a single amino
acid change in the receptor [44], deletions or truncations
have also been reported [45-47]. A number of recessive
mutations have also been reported to result in either MH
or CCD [48].
The identification of causative mutations suggests the
widespread use of DNA testing for MH, however, this is
confounded by the metabolic complexity and genetic het-
erogeneity of the disorder. Moreover, discordance
between MHS diagnosed by IVCT and the presence of
causative mutations has been shown within individual
families [49-55]. In most cases, genotype-phenotype dis-
cordance where MHS has been diagnosed by IVCT is likely
to be due to the presence of a separate mutation either in
RYR1 or at a separate locus [6,56]. False positive results for
the IVCT cannot be ruled out however, and probably
account for a small proportion of such discordance. False
positive results could be expected as the IVCT is not 100%
specific and could be due to an unrelated myopathic con-
dition. Until a greater understanding of the pathophysiol-
ogy of these other conditions and their relationship to the
MH phenotype is known, these patients would need to be
treated as MHS. Discordance in patients with a causative
mutation but who have been diagnosed MHN by IVCT
has also been reported by some testing laboratories [55].
As causative mutations clearly show altered calcium
release from intracellular stores, these rare instances of
discordance are likely to be due to a false negative diagno-
sis in the IVCT. Taken together, these observations suggest
that DNA testing should always be used in selected, genet-
ically characterized families, as well as within the guide-
lines for DNA testing identified by the EMHG [57] or the
NAMHG [58]. Using both IVCT and genetic diagnosis, a
higher proportion of true positives are likely to be identi-
fied than by simply relying on one or other test.
The guidelines set down by the EMHG requires contrac-
ture testing prior to genetic testing in a family. Once a
causative mutation is found in a family member, others
may be tested for susceptibility by seeking out that muta-
tion in the DNA. The predictive value of the genetic test
has been suggested to be ~50% based on correlation
between an MHS diagnosis by IVCT and presence of a
causative mutation [58]. Using the same criteria, 62% of
MHS patients in one family (36/58) were diagnosed MHS
by genetic testing [56]. Another study reported the predic-
tive value of genetic testing to be ~80% in a total of 10
families [55]. The sensitivity of the DNA test clearly varies
within populations but will likely increase as more muta-
tions are identified especially for those families where a
significant level of discordance has been observed.
In summary, because of the heterogeneity of the disorder,
as well as discordance within families, a negative DNA
result cannot be used to rule out MH susceptibility. In
addition, only those mutations that have been biochemi-
cally characterized to affect SR calcium release can be used
to test for MH susceptibility. Approximately 28 mutations
within RYR1 have been shown to cause an alteration in
calcium release from intracellular stores. A number of
functional tests have been used successfully to assess the
role of RYR1 mutations in calcium release. These include
the use of lymphoblastoid cell lines generated from MHS
individuals [59-61]. COS-7 or HEK293 cells transfected
with the cDNA for rabbit RYR1 carrying point mutations
introduced by site-directed mutagenesis [19,62,63], myo-
tubes generated from muscle biopsy tissue [44,64-66] and
1B5 dyspedic myotubes transduced with wild type and
mutated RYR1 cDNA [67]. Calcium release can be moni-
tored and quantified using calcium-specific indicators like
fluo-4 and fura-2 [68], [3H] ryanodine binding assays
[67,69], and, indirectly, by protein release [70]. Systems
using 1B5 dyspedic myotubes are more physiological as
they constitutively express all the components of the skel-
etal muscle with the exception of RYR1 [67]. They also
contain larger and more efficiency filled calcium stores
than do COS-7 or HEK 293 cells, thus providing a more
sensitive measure for calcium release and reloading. To
date, all mutations functionally characterized have been
shown to cause alterations in calcium flux through the
ryanodine receptor calcium release channel. It has been
argued that lymphoblastoid cells and myotubes derived
from MH patients can not be used to unambiguously
demonstrate altered physiological function, as the pheno-
type may be due not only to mutations in RYR1 but also
in other genes encoding protein components of the SR
calcium release channel. Nevertheless, these systems have
proved useful in demonstrating abnormal calcium release
associated with RYR1 mutations and it could be equally
argued that these systems are representative of the genetic
background of individual patients and therefore provide
valuable information ex vivo. As lymphoblastoid cell lines
do not express the dihydropyridine receptor, they could
also effectively be used to functionally test RYR1 muta-
tions as well as to eliminate RYR1 as a causative factor in
MH individuals who do not show linkage to RYR1.
A variety of minimally invasive diagnostic tests are in
development at present. One utilizes nuclear magnetic
resonance spectroscopy to evaluate ATP depletion during
graded exercise in vivo. MH patients have a greater break-
down of ATP and creatine phosphate, as well as an
increase in acid content compared to controls [38]. The
test requires expensive and sophisticated equipment and
a team well versed in interpreting the resultant tracings of
the peaks of ATP and inorganic phosphate. Insertion of a
microdialysis catheter into muscle and injection of a smallOrphanet Journal of Rare Diseases 2007, 2:21 http://www.OJRD.com/content/2/1/21
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amount of caffeine will elicit an enhanced release of car-
bon dioxide from the muscle tissue, which can be meas-
ured by capnography [71].
Differential diagnosis
A variety of unusual conditions may resemble MH during
anesthesia. These include sepsis, thyroid storm, pheochro-
mocytoma, and iatrogenic overheating. Hence, a high
index of suspicion for these disorders as well as the ability
to measure ETCO2 and obtain arterial and venous blood
gas analysis is essential in order to differentiate MH from
these disorders. Particularly problematic is the unex-
plained hyperthermia following anesthesia. Since anes-
thetic gases generally inhibit the febrile response, the first
sign of sepsis may be marked hyperthermia on emergence
from anesthesia. Response to antipyretics as well the clin-
ical setting is often helpful in differentiating this response
from MH.
The differential diagnosis of unexplained increased
ETCO2  includes hyperthermia secondary to sepsis, or
iatrogenic warming, machine valve malfunction,
rebreathing, as well as faulty equipment.
Outside the operating room, MH-like syndrome may
occur following injection of ionic contrast agents into the
cerebrospinal fluid, cocaine overdose, and the neurolept-
malignant syndrome(NMS).
NMS is a potentially fatal hyperthermic syndrome that
occurs as a result of ingestion of drugs used in the treat-
ment of mental and nervous conditions such as schizo-
phrenia. The incidence is approximately 0.01–0.02% of
those being treated with these drugs such as older as well
as newer antipsychotics and haloperidol, a sedative agent
often used in the ICU to treat agitation. Other dopamine
antagonists also have been reported to cause NMS.
The signs of NMS include muscle rigidity, acidosis, high
fever, rhabdomyolysis. The pathophysiology is thought to
result from dopamine receptor blockade. Treatment
includes benzodiazepines, bromocriptine and even dant-
rolene. There does not appear to be any cross over suscep-
tibility to MH or vice versa. There is no laboratory
diagnostic test for the syndrome either [72].
If a high ionic, water-soluble radiologic contrast agent is
injected intrathecally, usually as a result of drug mixup, a
characteristic progression of signs occurs. After the injec-
tion, the patient appears to recover normally, but within
thirty minutes involuntary jerking movements begin in
the lower extremities and ascend to the upper body,
finally resulting in seizures and hyperthermia. This is the
result of the contrast agent entering the cerebral ventricles
and requires a rapid symptomatic treatment of the muscle
activity, hyperthermia, and acidosis (cooling, nondepo-
larizing neuromuscular blockers, ventilation, and seda-
tion) [73]. The response of signs of hyperthermia,
tachycardia and tachypnea to dantrolene in such syn-
dromes is non-specific. In other words, the response to
dantrolene does not per se prove MH susceptibility.
In many countries, a "hotline" has been established to
provide emergency assistance in the management of MH.
Many are listed on the web site of the Malignant Hyper-
thermia Association of the US [74].
Hyperkalemic cardiac arrest in patients with muscular 
dystrophy
A syndrome often confused with MH is sudden hyperka-
lemic cardiac arrest during or shortly after anesthesia in
young males. Following sporadic reports of such arrests,
Larach and colleagues identified that patients with an
occult myopathy, especially a dystrophinopathy such as
Duchenne's muscular dystrophy, are at risk to dramatic
life-threatening hyperkalemia upon administration of
succinylcholine [75]. More recently, it has been shown
that administration of potent volatile agents to such
patients may produce a similar syndrome [76].
Since the most common muscular dystrophy (Duch-
enne's) is found with a frequency of 1 in 3500 live male
births, and the onset of symptoms of muscle weakness
may be as late as 6–8 years of age, some apparently
healthy children may really be at risk of succinylcholine
induced hyperkalemia. Hence, when a young child or
young adult experience a sudden and apparently unex-
pected cardiac arrest, think of hyperkalemia, document
and treat it in the standard fashion (calcium, bicarbonate,
glucose and insulin, and hyperventilation). Muscle tissue
should be obtained and preserved for testing for a myop-
athy, specifically a dystrophinopathy.
In general, the patient with a dystrophinopathy that
develops these anesthetic-related complications does not
also exhibit classic signs of MH, such as hypethermia or
marked muscle rigidity. They do, however, develop rhab-
domyolysis. Therefore, this reaction is not malignant
hypethermia  per se, since the dystrophinopathies are
caused by mutations on the X chromosome.
In response to the presentation of over 30 such cases to
the Food and Drug Agency (FDA) in 1992, a warning was
issued to avoid the use of the drug in children and young
adolescents for elective cases. Succinylcholine should be
reserved for those cases of full stomach and possibly air-
way related emergencies.Orphanet Journal of Rare Diseases 2007, 2:21 http://www.OJRD.com/content/2/1/21
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Rhabdomyolysis
Rhabdomyolysis refers to the breakdown of skeletal mus-
cle which is associated with excretion of myoglobin in the
urine. Classically, MH presents with hypercarbia, tachy-
cardia, cardiac arrhythmias, pyrexia, rigidity and meta-
bolic acidosis, and rhabdomyolysis as a late sign. Several
reports of isolated rhabdomyolysis apparent immediately
following anesthesia or developing up to 24 hours post
anesthesia have been published [77,78]. Increased creat-
ine kinase (CK) measurement and a positive IVCT have
been obtained in these patients, indicating MH suscepti-
bility. However, MH-like muscle responses can represent
false positive diagnoses and an underlying myopathic
process may produce a positive IVCT [79], so there must
remain some doubt on the validity of this feature i.e. rhab-
domyolysis as an expression of MH. Burns et al. however
stated that MH should be considered in all patients pre-
senting with rhabdomyolysis where the degree of muscle
necrosis exceeds that expected for the severity of the
accompanying disorder [80]. The most prudent diagnostic
course, therefore, is contracture testing for MH suscepti-
bility.
Genetic counseling
Genetic testing can be defined as an analysis or test that
confirms the presence or the absence of a genetic condi-
tion; this does not necessarily involve the analysis of DNA
as there are still many clearly genetic conditions where the
gene has not yet been identified. In the context of MH, the
IVCT could be considered to be just as much a genetic test
as the analysis of the RYR1 gene.
Genetic testing is different to the traditional medical test
in that not only will the result have potential ramifica-
tions for the current health of that individual, but it may
also have ramifications for the future health of that indi-
vidual and the future health of their immediate relatives
[81,82]. Depending on the test being performed, results
may leave the individuals disadvantaged in terms of their
ability to access health insurance or life insurance,
employment opportunities and, in some cultures, may
even affect marital opportunities [83,84]. For this reason
it is recommended that each individual accessing any
form of genetic testing and indeed each individual under-
going IVCT or RYR1 analysis should be fully informed of
all the implications of each potential result and should be
able to provide informed consent [85,86]. The process of
imparting this information and discussing any questions
the patient may have, is known as genetic counseling. This
discussion with a clinician or genetic counselor should
include the following points of information (Am. Soc.
Hum. Gen. 1975):
- Potential implications the result may have on their abil-
ity to obtain health/life insurance [87,88].
- Potential psychological effects of the result. Some par-
ents feel guilty that they may have passed MH sensitivity
on to their children, others may feel anxious about the
implications of a MH sensitivity result and experience an
increased fear of surgery, others may even feel guilty if
they have not inherited MH when their brother or sister
has [89-91].
- Inheritance pattern of the disorder and what implica-
tions their test result may have for their children and the
extended family.
If there is also a family history of CCD, it is important that
the potential diagnosis of this condition is not lost in the
discussions regarding MH. CCD is an extremely variable
condition within families and while some individuals
may only be very mildly affected, other family members
may have a more severe phenotype [15].
Interpreting risk for other family members
MH is an autosomal dominant condition. When initiating
genetic analysis in a branch of a known family, it is impor-
tant to test the individual at the highest risk first.
Parents of a proband
The large majority of times, an affected proband will have
inherited MH sensitivity from one of the parents. Clarifi-
cation of which parent may also be MHS is useful for iden-
tifying which side of the extended family (i.e. aunts and
uncles) may be at risk.
Siblings of a proband
The risk to the siblings depends of the genetic status of the
parents. If a parent is identified as MHS, then each of the
proband's siblings have a 1 in 2 or 50% chance of also
being MHS. If both parents receive an MHN result on
IVCT and RYR1 analysis – suggesting the mutation is de
novo in the proband – then the proband's siblings are at
no greater risk than the general population.
Offspring of a proband
The risk for offspring of each individual with proven MHS
also has a 50% chance of being MHS. The proband's
grandchildren would be considered to be at 25% risk until
their parent's genetic status is clarified.
Note: An individual who is MHN cannot pass MH sensi-
tivity on to the next generation, however, if they have an
affected parent, their siblings may still be at risk.
Interpretation of risk for other family members in the 
context of RYR1 analysis
As discussed in earlier sections, the identification of a
causative RYR1 mutation is sufficient to diagnose MH sen-
sitivity. However, due to current concerns regarding dis-Orphanet Journal of Rare Diseases 2007, 2:21 http://www.OJRD.com/content/2/1/21
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cordance between IVCT and mutation analysis in some
families, current protocols state that a negative mutation
result is not sufficient to identify a person as being MHN.
In the event of a normal (negative) mutation result, IVCT
is still recommended to confirm MHN status, and the
individual and his/her offspring are still considered to be
potentially MHS unless IVCT proves otherwise [54].
However, it is important to remember that in the event of
a normal (negative) mutation result, the offspring of the
individual are no longer at risk of inheriting the character-
ized family mutation. As the tested individual does not
carry the mutation, he cannot pass it on to his offspring.
Therefore, if an individual is mutation negative but IVCT
positive, the only useful test available to the offspring is
IVCT.
Final note on autonomy in clinical testing for MH
Some individuals may wish to delay IVCT or RYR1 analy-
sis, while they consider the information they have been
given and/or make the necessary preparations. Others
may decide that they do not want their risk clarified by
clinical testing. These decisions should be respected and
these individuals considered being MHS until proven oth-
erwise.
Care should then be taken when arranging testing for the
offspring of these individuals as a positive result in the
next generation will generate a result for the individual
who did not want to know (the individual must have car-
ried the gene mutation in order to pass it on).
Management and treatment
Acute MH crisis
The essential points in the treatment of acute MH crisis are
the immediate discontinuation of trigger agents, hyper-
ventilation, administration of dantrolene in doses of 2.5
mg/kg repeated prn (pro re nata) to limit MH, cooling by
all routes available (especially nasogastric lavage), and
treating hyperkalemia in a standard fashion. Calcium
blockers should not be used along with dantrolene, since
hyperkalemia may occur with such a drug combination.
The steps in the treatment of acute MH are as follows:
1. Stop potent inhalation agents and succinylcholine.
2. Increase minute ventilation to lower ETCO2.
3. Get help.
4. Prepare and administer dantrolene:
- 2.5 mg/kg initial dose;
- Titrate dantrolene to tachycardia and hypercarbia;
- 10 mg/kg suggested upper limit, but more may be given
as needed.
5. Begin cooling measures:
- If hyperthermic, use iced solutions, i.e. Ice Packs to groin,
axilla, and neck;
- Nasogastric lavage with iced solution;
- More aggressive measures as needed;
- Stop cooling measures at 38.5°C.
6. Treat arrhythmias as needed. Do not use calcium chan-
nel blockers.
7. Secure blood gases, electrolytes, creatine kinase, blood
and urine for myoglobin;
- Coagulation profile check values every 6–12 hours;
- Treat hyperkalemia with hyperventilation, glucose and
insulin as needed;
- Once crisis is under control, an MH hotline should be
contacted for further guidance.
8. Continue dantrolene at 1 mg/kg every 4–8 hours for
24–48 hours.
9. Insure urine output of 2 ml/kg/hour with mannitol,
furosemide, and fluids as needed.
10. Evaluate need for invasive monitoring and continued
mechanical ventilation.
11. Observe patient in Intensive Care Unit for at least 36
hours.
12. Refer patient and family to MH Testing Center for con-
tracture or DNA testing.
Patients experiencing MH should receive dantrolene and
be monitored closely for 48–72 hours, since (even despite
dantrolene treatment) 25% of patients will experience a
recrudescence of the syndrome. Tests for disseminated
intravascular coagulation (DIC) should be included, as
well as observation of the urine for myoglobinuric renal
failure. DIC is most frequent when body temperature
exceeds about 41°C.
Preventive measures
Preventive measures include a thorough anesthetic history
to determine the possibility of the patient or a familyOrphanet Journal of Rare Diseases 2007, 2:21 http://www.OJRD.com/content/2/1/21
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member having experienced an MH episode. When suspi-
cion of MH exists, family members should not be given
trigger anesthetic agents, i.e. potent volatile anesthetic
agents such as halothane, sevoflurane, desflurane, enflu-
rane, isoflurane and succinylcholine, and testing is recom-
mended.
Patients with any form of myotonia should not receive
succinylcholine. Patients with hypokalemic periodic
paralysis, CCD, Duchenne or Becker muscular dystrophy,
paramyotonia, or myotonia fluctuans should not receive
trigger agents.
All patients receiving more than a brief general anesthetic
should have their core temperature monitored.
Young patients (below age 12 approximately) should not
receive succinylcholine for elective procedures, in order to
avoid the possibility of hyperkalemic response in a patient
with undiagnosed muscular dystrophy.
Patients who are MH susceptible should be cautioned
regarding the remote, but conceivable possibility of heat
stroke in environments in which exposure to high heat
and humidity is possible.
Management of the MH susceptible for anesthesia
Patients who are known to be MH susceptible may be
anesthetized with regional anesthesia or local anesthesia
without problems. If general anesthesia or sedation is
required, the potent volatile agents and succinylcholine
should be avoided.
The anesthesia machine should be prepared by flowing
100% oxygen through the machine at 10 L/min for at least
20 minutes. The ventilator should also be included in
purging the machine by cycling the ventilator at the time
of the oxygen flow. Vaporizers should be disabled,
drained or removed if possible. All intravenous agents and
nondepolarizing relaxants are safe to use.
Once the patient has undergone such an anesthetic with-
out incident, he/she may be treated similar to any other
patients. It is no longer felt to be necessary to monitor
such patients in the post-anesthesia care unit for four




Given the confidence provided by functional analysis of
RYR1  mutations, the problem of discordance between
RYR1  mutations and MHS and MH equivocal (MHE)
diagnosis still remains the largest problem associated with
genetic diagnosis of susceptibility to MH. The MHE diag-
nosis is the most problematic and exhibits a much higher
level of discordance than does MHS. Correlation between
RYR1 mutations and IVCT is greater for the caffeine (c)
than the halothane (h) response [92] suggesting that the
MHE(c) has greater diagnostic potential. The NAMHG
protocol does not allow the MHE diagnosis; the potential
for discordance between IVCT phenotype and RYR1 geno-
type is therefore much greater. In a large UK study investi-
gating the relationship between RYR1 genotype and IVCT
phenotype, discordance was identified in seven families
(nine individuals), with five false-positives and four false-
negatives [20]. Mutation negative MHS individuals have
also been observed [20,55] (Recent unpublished data give
an approximate 2.5% discordance rate of this type in a
large series of UK patients). Clear evidence of the involve-
ment of genes as well as RYR, has been shown in a New
Zealand Maori pedigree where MHS correlates with a
T4826I mutation [56]; but three branches of the family
possess unrelated chromosome 19 haplotypes, without
the T4826I mutation in unambiguous MHS individuals
spanning three or four generations. While some discord-
ance may be explained by the existence of other yet uni-
dentified mutations, false positive IVCT tests [93] and
weak contracture mutations [20] have also been impli-
cated. Clearly, while genetic diagnosis can be used selec-
tively, a greater knowledge of the molecular mechanisms
resulting in susceptibility to MH is required before the
IVCT can be dispensed with.
Awake MH
In 1966 the Porcine Stress Syndrome was identified as an
"awake" malignant hyperthermia episode. Stresses such as
fighting cause a rapid death in these animals. In 1974
Wingard described an MH susceptible family with exercise
and emotional induced pyrexia, in sudden deaths unre-
lated to surgery. He considered that MH was part of a
human stress syndrome. Subsequently, a number of
reports of MH reactions in patients given trigger-free anes-
thetics appeared. None of these reactions were totally con-
vincing.
However, Gronert and Denborough, both reported
patients with "awake" MH episodes, the latter being
patients with exercise-induced heat stroke who responded
to dantrolene [94-96]. Perhaps the most convincing,
though unfortunate, episode of exercise induced MH was
reported by Tobin et al., a fatal episode in a 13-year-old
boy who had experienced a clinical episode of MH and
developed signs of MH following exercise some months
later. He and other family members were found to have a
causative RYR 1 mutation [97]. Brown et al. reported a
possible viral trigger [56].
Further physiological evidence of stress-related MH has
been demonstrated by pH changes in MHS muscle recov-Orphanet Journal of Rare Diseases 2007, 2:21 http://www.OJRD.com/content/2/1/21
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ering from violent exercise [98]. The sympathetic nervous
system appears to be only secondarily involved [99], but
serotonin (5HT) agonists may cause an MH-like syn-
drome in susceptible pigs [100]. These agents can also
cause MHS contractures in susceptible muscle [101]. Does
serotonin have a role in the stress-induced episodes?
There is limited support for this [102,103]. Recent
research in mice with the Y522S mutation indicates
abnormal sensitivity to increased environmental temper-
atures associated with abnormal calcium release. This lat-
est report, however, should be considered with some
caution as the homozygous Y522S mutation in mouse is
embryonic lethal, which is a different phenotype to that
observed with the homozygous R615C mutation in pigs
and the small number of homozygous RYR1 mutations in
humans which clearly do not cause embryonic lethality. A
more recent study, however, reports that a "knock-in"
mouse heterozygous for the R163C RYR1  mutation is
more representative of the human phenotype and thus
may provide an important model system for further study
of awake-MH [104].
Wappler et al. described a 34-year-old male with recurrent
fever, fatigue, muscle cramping, and aching with mild
exercise and emotional stress [105]. IVCT demonstrated
an MHS response and a "causative" mutation. Others
have reported similar findings [106,107]. A possible con-
clusion is that a small subset of MH patients may display
muscle damage and perhaps more ominous signs with the
stress of exercise, and may be other stresses. It is recom-
mended that MH is excluded in patients who have had
episodes of exert ional heat stroke [108]. Despite possible
links between exertional heat stroke and MH however,
treatment with dantrolene has had limited results, thus
this drug should not be used routinely in the management
of heat stroke.
Resources
Many anesthesia textbooks, web sites and articles contain
very thorough descriptions of MH and related syndromes.
However, these sources often fail to provide information
for patients (patient-specific information). Various volun-
tary organizations throughout the world are dedicated to
assisting patients, physicians, anesthesia providers of all
types and any one else in managing the MHS and keeping
these individuals up to date with the latest information
regarding MH.
In the United States, the Malignant Hyperthermia Associ-
ation of the United States (MHAUS) provides newsletters,
printed information, an informative website [75] to meet
the needs of the various groups interested in MH. In addi-
tion, a hotline provides direct consultation for providers
in real time management of MH episodes or questions
related to specific patient as to their likelihood of develop-
ing MH and the optimum management of an episode.
MHAUS, similar to other MH patient advocacy organiza-
tions is not for profit supported by voluntary contribu-
tions. The North American MH Registry supports a
patient-specific database with detailed information as to
the phenotypic presentations as well as diagnostic test
results. The Registry is a subsidiary of MHAUS and is
located at Children's Hospital of Pittsburgh [109].
The European MH group [110] coordinates testing proce-
dures throughout Europe and is made up of professionals
investigating MH. Patient supported MH associations
exist in France, Germany, Switzerland, Japan, United
Kingdom and several other countries. In South Africa,
issues related to MH are subsumed under the Muscular
Dystrophy Association of that country. These organiza-
tions have been crucial to the education of anesthesia pro-
viders in diagnosing and managing MH and helping
patients better understand the disorder.
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